Granisetron Transdermal Patch clinical trials
How each study uses Granisetron Transdermal Patch is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Granisetron Transdermal Patch studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2020 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 3
Kyowa Kirin Pharmaceutical Development Ltd (1) · Kyowa Kirin, Inc. (1) · University of Illinois Chicago (1) · University of Southern California (1) · Fudan University (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of 5-HT3 antagonists source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Granisetron Transdermal Patch.
- Mar 2027BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to OndansetronPhase 4 · University of Illinois Chicago
Studies
Open first, then newest update. How each study uses Granisetron Transdermal Patch is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to OndansetronRecruitingPhase 4University of Illinois ChicagoNCT04150614Written as Granisetron Transdermal Patch
- Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 YearsCompletedPhase 1Kyowa Kirin Pharmaceutical Development LtdNCT01596400Written as granisetron transdermal system
- Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches.CompletedPhase 1Kyowa Kirin, Inc.NCT05027646Written as Sancuso - Part 1
- Granisetron Transdermal Patch for Prophylaxis of Delayed CINVStatus unknownPhase 3Fudan UniversityNCT04912271Written as Granisetron transdermal patch
- Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing ChemotherapyTerminatedPhase 1University of Southern CaliforniaNCT01649258Written as granisetron transdermal system